AstraZeneca prepares to live with the IRA, shifting focus of arguments to orphan drug changes

NEW YORK — AstraZeneca may be getting ready to live with the Inflation Reduction Act.

On Friday morning, CEO Pascal Soriot told reporters that the drugmaker is most focused on getting the 2022 law adjusted, not invalidated. His comments are the most direct yet from a major pharma CEO about a future in which the IRA is not fully overturned by the courts, as several drugmakers have sued to try and do.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

Novel Vaccines Promising for Chikungunya, Cytomegalovirus

BOSTON — Vaccine candidates for chikungunya virus and for the ubiquitous cytomegalovirus performed well in human clinical trials, researchers reported here at the annual IDWeek

October 17, 2023

Atezolizumab Consolidation Impresses in High-Risk DLBCL

Postchemotherapy consolidation with atezolizumab (Tecentriq) led to a surprisingly high 2-year disease-free survival (DFS) in high-risk diffuse large B-cell lymphoma (DLBCL), a prospective nonrandomized trial

June 15, 2024

HPV Tumor DNA May Offer Early Warning of Cervical Cancer at High Risk of Relapse

HPV-positive circulating tumor (ct)DNA after chemoradiation (CRT) for cervical cancer had an independent association with worse outcomes, suggesting potential as a biomarker to guide decision-making,

November 22, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.